Ronald Li
Directeur Général chez Xellera Therapeutics Ltd
Fortune : 210 000 $ au 30/04/2024
Profil
Ronald Li was the founder of Novoheart Holdings, Inc. (founded in 1964) and held the title of Director from 1964 to 2016.
Dr. Li is also the founder of Novoheart Holdings Ltd.
Dr. Li's current job(s) include being the Chief Executive Officer & Director at Xellera Therapeutics Ltd, Director-Ming Wai Lau Centre at Karolinska Institutet (since 2016), Director-Stem Cell & Regenerative Medicine at the University of Hong Kong, Chief Scientific Officer at Sardocor Corp.
(since 2020), and Professor at Dr. Li Dak-Sum Research Centre.
Dr. Li's former job(s) include being a Director at Woodrose Ventures Corp., Co-Director-Cardiac Tissue & Cell Engineering at Icahn School of Medicine at Mount Sinai, Independent Director at Keen Vision Acquisition Corp.
(from 2021 to 2024), Associate Professor at the University of California, Davis, and Assistant Professor at The Johns Hopkins University School of Medicine.
Dr. Li's education history includes a doctorate from the University of Toronto and an undergraduate degree from The University of Waterloo.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 25/07/2023 | 20 000 ( 0,10% ) | 210 000 $ | 30/04/2024 |
Postes actifs de Ronald Li
| Sociétés | Poste | Début |
|---|---|---|
| Karolinska Institutet | Corporate Officer/Principal | 01/01/2016 |
Xellera Therapeutics Ltd
 Xellera Therapeutics Ltd Medical/Nursing ServicesHealth Services Part of Novomed Ltd., Xellera Therapeutics Ltd is a Chinese company that operates commercial current Good Manufacturing Practice (cGMP) facilities for clinical-grade cell and gene therapy products. The company is based in Hong Kong, Hong Kong. Xellera's state-of-the-art cGMP labs follow international standards to ensure quality, safety, and efficacy of Advanced Therapy Medicinal Products (ATMP). Xellera provides a one-stop solution to cGMP manufacturing, spanning from early process development to manufacturing and analytical testing, product release as well as cryostorage. The company was founded in 2018 and the CEOs are Roger Ngan and Ronald Li. Xellera Therapeutics was acquired by Novoheart Holdings, Inc., part of Novomed Ltd. from November 23, 2020 on June 28, 2019 for $18.71 million. | Directeur Général | - |
| University of Hong Kong | Corporate Officer/Principal | - |
| Sardocor Corp. | Directeur Technique/Scientifique/R&D | 01/06/2020 |
| Dr. Li Dak-Sum Research Centre | Corporate Officer/Principal | - |
Anciens postes connus de Ronald Li
| Sociétés | Poste | Fin |
|---|---|---|
| KEEN VISION ACQUISITION CORPORATION | Directeur/Membre du Conseil | 13/03/2024 |
| Icahn School of Medicine at Mount Sinai | Corporate Officer/Principal | - |
| University of California, Davis | Corporate Officer/Principal | - |
| The Johns Hopkins University School of Medicine | Corporate Officer/Principal | - |
| ░░░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ | - |
Formation de Ronald Li
| University of Toronto | Doctorate Degree |
| The University of Waterloo | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KEEN VISION ACQUISITION CORPORATION | Finance |
| Entreprise privées | 6 |
|---|---|
Woodrose Ventures Corp.
 Woodrose Ventures Corp. Miscellaneous Commercial ServicesCommercial Services Woodrose Ventures Corp. is a development stage company, which seeks to develop and exploit oil fields using development concepts and offshore production and storage facilities. The company was founded on April 28, 1964 and is headquartered in Vancouver, Canada. | Commercial Services |
Novoheart Holdings Ltd.
 Novoheart Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Novoheart Holdings Ltd. engages in stem cell biotechnology. The company is based in Hong Kong, Hong Kong. Novoheart Holdings was founded by Ronald Li. | Commercial Services |
Novoheart Holdings, Inc.
 Novoheart Holdings, Inc. BiotechnologyHealth Technology Novoheart Holdings, Inc. is a global stem cell biotechnology company. It engages in engineering prototypes of bio-artificial human heart tissues and chambers for drug discovery, cardio toxicity screening, diseases modeling and therapeutic applications. The firm products include Human Ventricular Cardiomyocytes (hvCM), Cardiac Anisotropic Sheet (hvCAS), Cardiac Anisotropic Patch (hvCAP), Cardiac Tissue Strip (hvCTS), and novoHeart. The company was founded by Michelle Khine, Kevin Costa and Ronald Li on April 28, 1964 and is headquartered in Vancouver, Canada. | Health Technology |
Xellera Therapeutics Ltd
Xellera Therapeutics Ltd Medical/Nursing ServicesHealth Services Part of Novomed Ltd., Xellera Therapeutics Ltd is a Chinese company that operates commercial current Good Manufacturing Practice (cGMP) facilities for clinical-grade cell and gene therapy products. The company is based in Hong Kong, Hong Kong. Xellera's state-of-the-art cGMP labs follow international standards to ensure quality, safety, and efficacy of Advanced Therapy Medicinal Products (ATMP). Xellera provides a one-stop solution to cGMP manufacturing, spanning from early process development to manufacturing and analytical testing, product release as well as cryostorage. The company was founded in 2018 and the CEOs are Roger Ngan and Ronald Li. Xellera Therapeutics was acquired by Novoheart Holdings, Inc., part of Novomed Ltd. from November 23, 2020 on June 28, 2019 for $18.71 million. | Health Services |
| Sardocor Corp. | |
| Dr. Li Dak-Sum Research Centre |
